Delayed Prostate Cancer Therapy Rochester NY

The evidence seems to contradict the assumption that living with untreated prostate cancer is nerve-wracking for most patients, according to Dr. Roderick van den Bergh, of Erasmus Medical Center in Rotterdam, and colleagues.

Local Companies

GORDON PHILLIPS, MD
(585) 275-0784
601 Elmwood Avenue
Rochester, NY
RAMAN QAZI, MD
(585) 341-6622
1000 South Avenue
Rochester, NY
Brent Du Beshter, MD
585-442-8020
125 Lattimore Rd Ste 258
Rochester, NY
Craig Anthony Mullen, MD
713-792-3314
601 Elmwood Ave
Rochester, NY
Eric A Singer, MD, MA
585-275-2222
601 Elmwood Ave # 656
Rochester, NY
Bingren Liu
(585) 225-3989
1561 Long Pond Rd
Rochester, NY
DEBORAH MULFORD, MD
(585) 275-0784
601 Elmwood Avenue
Rochester, NY
BARBARA ASSELIN, MD
(585) 275-7787
601 Elmwood Avenue
Rochester, NY
George B Segel, MD
585-275-2981
601 Elmwood Ave # 777
Rochester, NY
Swati Kishanjit Basu, MD
585-275-2981
601 Elmwood Ave # 644
Rochester, NY
Data Provided by:
    

Provided By:

MONDAY, July 27 (HealthDay News) -- Men who delay treatment for their early prostate cancer are not especially anxious about living with the disease, new Dutch research shows.

The evidence seems to contradict the assumption that living with untreated prostate cancer is nerve-wracking for most patients, according to Dr. Roderick van den Bergh, of Erasmus Medical Center in Rotterdam, and colleagues. The findings are published in the Sept. 1 issue of Cancer.

The researchers surveyed 129 men regarding their levels of depression and anxiety over their treatment decision. More than 80 percent scored favorably low and compared well emotionally with patients who had opted for more aggressive treatment, the study found.

Men who were in poor general health and those with neurotic personalities expressed higher levels of anxiety and distress, suggesting that factors other than cancer may impact a patient's emotional response, the researchers noted.

The study is especially useful in an era when prostate-specific antigen tests and other screening exams are uncovering prostate cancer at increasingly earlier stages. Many physicians practice a "wait-and-see" approach to treatment, saving the more aggressive therapies for when the cancer grows or spreads, according to information in a news release from the American Cancer Society.

Nationally, prostate cancer is one of the most common cancers and is expected to strike more than 190,000 men this year, and result in over 27,000 deaths, according to the American Cancer Society. But thanks to more effective screenings and treatments, while one in six U.S. men will develop prostate cancer during their lifetime, only one in 35 will actually die of the disease. What's more, there are more than 2 million men in the United States who have been diagnosed with prostate cancer at some point and are still alive today, according to the society.

More information

The U.S. National Cancer Institute has more on prostate cancer.

SOURCE: American Cancer Society, news release, July 27, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Head and Neck Cancer Treatment Rochester NY
Incomplete and interrupted radiation treatment is a common problem among Medicare patients with head and neck cancer, a new study has found. Researchers analyzed data from 5,086 Medicare patients diagnosed with head and neck cancer between 1997 and 2003 and found that nearly 40 percent of them experienced interruptions in radiation therapy or failed to complete the course of therapy.
- Hormone Therapy for Early Prostate Cancer Rochester NY
- Diagnosis of Prostate Cancer Rochester NY
- Hormone Therapy for Lung Cancer Rochester NY
- Hormone Therapy for Prostate Cancer Rochester NY
- Exercise for Prostate Cancer Rochester NY
- Drug Combo Proves Powerful Against Lung Cancer Rochester NY
- Hormone Therapy for Breast Cancer Rochester NY
- Open Prostatectomy Versus Laparoscopic Procedure Rochester NY
- Attack Of The Cancer Fighting Tomatoes Rochester NY